Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030

Overview
‘Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hidradenitis Suppurativa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hidradenitis Suppurativa (HS) Understanding
According to the National Organization of Rare Disorders, HS is a chronic condition characterized by swollen, painful lesions, occurring in the armpit, groin, anal and breast regions. It is painful and long-term skin condition causing abscesses and scarring on the skin. Affected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. Although foreign body type granulomas are a common finding in HS, the presence of discrete epithelioid granulomas in the dermis away from the site of active inflammation is unusual and should alert the pathologist to the possibility of a systemic granulomatous disease like Crohn’s disease (CD) or sarcoidosis. The longstanding disease can result in fibrosis, dermal contractures, significant scarring, the formation of fistulae, and rarely malignant transformation to squamous cell carcinoma
Hidradenitis Suppurativa (HS) Epidemiology Perspective by Report
The HS epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The HS epidemiology data are studied through HS possible division to give a better understanding of the Disease scenario in 7MM. The HS epidemiology is segmented by Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS covering the US, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Hidradenitis Suppurativa Detailed Epidemiology Segmentation
The HS epidemiology covered in the report provides historical as well as forecasted epidemiology {Total Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, Stage-Specific prevalent Cases, and Treated Prevalent Cases of HS} scenario of HS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
The Report HS report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
• The HS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The HS Report and Model provide an overview of the risk factors and global trends of HS in the seven major markets (7MM: US, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of HS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of HS
• The report provides the segmentation of the HS epidemiology by Age-specific diagnosed prevalent Cases of HS in 7MM
• The report provides the segmentation of the HS epidemiology by Gender-specific diagnosed prevalent Cases of HS in 7MM
• The report provides the segmentation of the HS epidemiology by Stage-Specific diagnosed prevalent Cases of HS in 7MM
Report Highlights
• 11-Year Forecast of Hidradenitis Suppurativa epidemiology
• 7MM Coverage
• Total Diagnosed prevalent Cases of Hidradenitis Suppurativa
• Diagnosed Prevalent Cases according to segmentation: Gender-specific, Age-specific, Stage-specific Incidence
• Treated cases of Hidradenitis Suppurativa
KOL-Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over HS scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?
• What are the key findings pertaining to the Hidradenitis Suppurativa epidemiology across 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Hidradenitis Suppurativa across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the study period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Hidradenitis Suppurativa?
• What are the current available treatments of Hidradenitis Suppurativa?
Reasons to buy
The Hidradenitis Suppurativa Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Hidradenitis Suppurativa market
• Quantify patient populations in the global Hidradenitis Suppurativa market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hidradenitis Suppurativa therapeutics in each of the markets covered
• Understand the magnitude of Hidradenitis Suppurativa population by its severity
• The Hidradenitis Suppurativa epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Hidradenitis Suppurativa Epidemiology Model developed by Report is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Most of the HS cases remain underdiagnosed, the diagnosed prevalent population of HS in Seven major markets was 1,210,785 in 2017 which is anticipated to increase by 2030. The estimates show highest diagnosed prevalent population of HS is in the United States. Among the European 5 countries, the Germany had highest diagnosed prevalent population of HS, followed by France, and the United Kingdom. On the other hand, Spain had the lowest prevalent population of HS in 2017.
As per analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries and highest proportion of HS cases were observed in 30–39 years age group among all the countries. It has been observed that Severe HS cases are comparatively very less from mild and moderate cases